Form 34 Oed CR FB Reviewer Worksheet

NCI Pediatric CIRB
REVIEWER WORKSHEET
Continuing Review of Cooperative Group Protocol

OMB #0925-xxxx Expiry Date: xx/xx/xxxx
ŽůůĞĐƚŝŽŶŽĨƚŚŝƐŝŶĨŽƌŵĂƚŝŽŶŝƐĂƵƚŚŽƌŝnjĞĚďLJdŚĞWƵďůŝĐ,ĞĂůƚŚ^ĞƌǀŝĐĞĐƚ͕^ĞĐƚŝŽŶϰϭϭ;ϰϮh^ϮϴϱĂͿ͘ZŝŐŚƚƐŽĨLJŽƵƌƉĂƌƚŝĐŝƉĂƚŝŽŶ
ŝŶƚŚĞE//ZŝƐƉƌŽƚĞĐƚĞĚďLJdŚĞWƌŝǀĂĐLJĐƚŽĨϭϵϳϰ͘WĂƌƚŝĐŝƉĂƚŝŽŶŝƐǀŽůƵŶƚĂƌLJ͕ĂŶĚƚŚĞƌĞĂƌĞŶŽƉĞŶĂůƚŝĞƐĨŽƌŶŽƚƉĂƌƚŝĐŝƉĂƚŝŶŐŽƌ
ǁŝƚŚĚƌĂǁŝŶŐĨƌŽŵƚŚĞE//ZĂƚĂŶLJƚŝŵĞ͘ZĞĨƵƐĂůƚŽƉĂƌƚŝĐŝƉĂƚĞǁŝůůŶŽƚĂĨĨĞĐƚLJŽƵƌďĞŶĞĨŝƚƐŝŶĂŶLJǁĂLJ͘dŚĞŝŶĨŽƌŵĂƚŝŽŶĐŽůůĞĐƚĞĚ
ǁŝůůďĞŬĞƉƚƉƌŝǀĂƚĞƚŽƚŚĞĞdžƚĞŶƚƉƌŽǀŝĚĞĚďLJůĂǁ͘EĂŵĞƐĂŶĚŽƚŚĞƌŝĚĞŶƚŝĨŝĞƌƐǁŝůůŶŽƚĂƉƉĞĂƌŝŶĂŶLJƌĞƉŽƌƚŽĨƚŚĞE//Z͘
/ŶĨŽƌŵĂƚŝŽŶƉƌŽǀŝĚĞĚǁŝůůďĞĐŽŵďŝŶĞĚĨŽƌĂůůƉĂƌƚŝĐŝƉĂŶƚƐĂŶĚƌĞƉŽƌƚĞĚĂƐƐƵŵŵĂƌŝĞƐ͘zŽƵĂƌĞďĞŝŶŐƌĞƋƵĞƐƚĞĚƚŽĐŽŵƉůĞƚĞƚŚŝƐ
ŝŶƐƚƌƵŵĞŶƚƐŽƚŚĂƚǁĞĐĂŶĐŽŶĚƵĐƚĂĐƚŝǀŝƚŝĞƐŝŶǀŽůǀĞĚǁŝƚŚƚŚĞŽƉĞƌĂƚŝŽŶƐŽĨE//Z/ŶŝƚŝĂƚŝǀĞ͘
NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for
reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the
collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705
Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-xxxx*). Do not return the completed form to this address.

STUDY ID:
STUDY TITLE:
NAME OF CIRB REVIEWER:
DATE COMPLETED:

1.

I have reviewed the following documents (check all that apply):
NCI Adult/Pediatric CIRB Application for Continuing Review
Study Protocol
Cooperative Group Model Informed Consent Document(s)
CIRB Approved Informed Consent Document(s)
DSMB/Safety Monitoring Committee Report
Presentations or publications for the study
Relevant information relating to participants’ risks and benefits
Management plan to address new or revised conflicts of interest
Other (specify):

2.

Are there any important changes in the risks, benefits, or protocol
schedule that you believe have an impact on the CIRB's approval of this
protocol?
No

Adapted from ePanel© 08/19/16

Yes

3.

In your judgment, do the benefits of this study continue to outweigh the
risks?

4.

Yes
No
Uncertain
If No or Uncertain, please explain:

5.

Do you recommend that the CIRB approve continuation of this study?
Yes
No
Uncertain

6.

If No or Uncertain, please explain:

7.

Additional Remarks.

Pediatric Risk Assessment
8.

45 CFR 46.404: Research no involving greater than minimal risk
Minimal Risk
Explanation based on study documentation:
Adequate provisions are made for soliciting the assent of the children and
the permission of their parents or guardians, as set forth in 46.408.
Explanation based on the study documentation:

Permission required from
One Parent
Both Parents
9.

45 CFR 46.405: Research involving greater than minimal risk but presenting
the prospect of direct benefit to the individual subjects
Greater than minimal risk
Explanation based on study documentation:
Prospect for direct subject benefit
Explanation based on study documentation:
The risk is justified by the anticipated benefit to the subjects
Explanation based on study documentation:

Adapted from ePanel© 08/19/16

The relation of the anticipated benefit to the risk is at least as favorable to
the subjects as that presented by available alternative approaches
Explanation based on study documentation:
Adequate provisions are made for soliciting the assent of the children and
permission of their parents or guardians, as set forth in 46.408.
Explanation based on study documentation:
Permission required from
One Parent
Both Parents
10.

45 CFR 46.406: Research involving greater than minimal risk and no
prospect of direct benefit to individual subjects, but likely to yield
generalizable knowledge about the subject's disorder or condition
Greater than minimal risk
Explanation based on study documentation:
The risk represents a minor increase over minimal risk
Explanation based on study documentation:
The intervention or procedure presents experiences to subjects that are
reasonably commensurate with those inherent in their actual or expected
medical, dental, psychological, social, or educational situations
Explanation based on study documentation:
The intervention or procedure is likely to yield generalizable knowledge
about the subjects' disorder or condition which is of vital importance for
the understanding or amelioration of the subjects' disorder or condition
Explanation based on study documentation:
Adequate provisions are made for soliciting assent of the children and
permission of their parents or guardians, as set forth in 46.408. Both
parents will provide permission.
Explanation based on study documentation:

11.

45 CFR 46.407: Research not otherwise approvable which presents an
opportunity to understand, prevent, or alleviate a serious problem affecting the
health or welfare of children

The IRB does not believe meets the requirements of 46.404,
46.405, 46.406
Explanation based on study documentation:
The IRB finds that the research presents a reasonable opportunity to
further the understanding, prevention, or alleviation of a serious problem
affecting the health or welfare of children
Explanation based on study documentation:

Adapted from ePanel© 08/19/16

12.

45 CFR 46.408: Requirements for assent by children

Assent requirement waived
Capability of some or all of the children is so limited that they cannot
reasonably be consulted
OR
Procedure involved in the research holds out a prospect of direct benefit
that is important to the health or well-being of the children AND the
intervention is available only in the context of the research
OR
Assent may be waived in accord with 45 CFR 46.116
Explanation based on study documentation:
Assent required
Age where assent is expected. Standard age ranges will be determined
and provided as options.

13.

Questions for the Study Team
Questions included below will be sent to the Study Team in advance of the CIRB
meeting. Whenever possible, CIRB Operations Office staff will forward responses
received prior to the meeting to the primary reviewers and post those responses
in ePanel. In order to ensure questions are sent to the Study Chair, questions
should be posted here in ePanel at least 36 hours prior to the CIRB meeting.

14.

Topics for CIRB Discussion
List below any topics requiring discussion among the CIRB members prior to a
final assessment of the study (e.g. whether inclusion of individuals with impaired
decision-making is appropriate).

15.

Proposed Stipulations
Changes or additional information that the CIRB requires before the study can be
approved should be listed below. The changes or requested information must
pertain to the regulatory criteria for approval or have a direct impact on the
protection of study participants.

16.

Recommendations
List recommended changes below. Recommended changes do not relate to the
regulatory criteria for approval nor do they relate to protection of study
participants. The Study Chair may opt to address the recommendations, or may
disregard them.

Adapted from ePanel© 08/19/16

Adapted from ePanel© 08/19/16